Meet the Biopharma Investment Banking Team

Andrew “Cal” Callaway

Andrew “Cal” Callaway

Global Head, Healthcare Investment Banking

Andrew 'Cal' Callaway is the Global Head of Healthcare Investment Banking at RBC Capital Markets. He is responsible for coverage of healthcare banking clients and prospects across the sector, including some of the largest pharmaceutical companies in the world. Andrew has over 20 years of investment banking experience and has advised on over 150 M&A and financing transactions in the biopharmaceutical sector. Andrew graduated from Amherst College. He is married with three children.

Ahmed Attia

Ahmed Attia

Managing Director, Healthcare M&A

Ahmed joined RBC in 2019 as a Managing Director in M&A and leads RBC Capital Markets’ healthcare M&A practice.  He has extensive M&A experience working with both corporate clients and financial sponsors.  Ahmed has worked on deals totaling over $75bn+ over last 15 years.  He has led numerous complex / global transactions on both the buy side and sell side.  Ahmed also works with clients on evaluating a range of strategic alternatives.

Noël Brown

Noël Brown

Managing Director and Head, US Biotechnology Investment Banking

Noël Brown is a Managing Director in Global Healthcare Investment Banking at RBC Capital Markets focused on the biopharmaceuticals sector. Noël has over 20 years of experience in the securities industry. Noël graduated from the University of Western Ontario and received a law degree from the University of Ottawa and a MBA from the MIT Sloan School of Business.

Jason Levitz

Jason Levitz

Managing Director, Healthcare Equity Capital Markets

Jason Levitz is the Head of Healthcare Equity Capital Markets at RBC Capital Markets. He joined RBC Capital Markets in 2012 and has worked in capital markets and investment banking for over 25 years.  Jason has extensive experience leading origination and execution activities for biotech and pharma companies, as well as companies across the healthcare industry. He received a BA from Yale and received his MBA from Columbia Business School.

Vince Lozada

Vince Lozada

Managing Director, Biopharmaceuticals

Vincent Lozada is a Managing Director in the Global Healthcare Investment Banking Group at RBC Capital Markets focused on the biopharma sector. Vince has almost 20 years of investment banking experience.  He graduated from Rutgers University with a B.S. in Finance, received his MBA with Honors from The University of Chicago Booth School of Business and completed the Advanced Biosciences program at the University of California, Berkeley.  In addition, Vince is a CFA charterholder.

Tim Papp

Tim Papp

Managing Director, Biopharmaceuticals

Tim Papp is a Managing Director in Global Healthcare Investment Banking at RBC Capital Markets focused on the biopharmaceuticals sector. He has 20+ years of investment banking experience and has focused on the biopharma sector since 2007. Tim is responsible for origination and execution of financing and strategic advisory transactions, primarily for small and mid-cap public and private companies. He has extensive experience raising capital for biotechnology and specialty pharmaceuticals companies across a range of products, including IPOs, follow-on offerings, private placements and convertible and non-convertible debt offerings.

Thomas Stockman

Thomas Stockman

Head, European Healthcare Investment Banking

Tom is a Managing Director and Head of European Healthcare Investment Banking, based in London. He leads RBC’s activities with European healthcare companies with deep experience across the industry, including advising and financing large cap pharma, generics, specialty and biotech companies, as well as private equity sponsors. Tom has 20 years of investment banking experience and has been part of the RBC team since 2015. He holds an MA in Biological Sciences from Oxford University.

Greg Wiederrecht, Ph.D.

Greg Wiederrecht, Ph.D.

Managing Director, Biopharmaceuticals

Greg Wiederrecht is a Managing Director in Global Healthcare Investment Banking at RBC Capital Markets, principally focused on large-cap pharma, mid-cap pharma and the biotechnology sectors. He was previously the Vice President and Head of External Scientific Affairs (ESA) at Merck & Co., Inc. where he was employed for 25 years. Within the Worldwide Licensing & Acquisitions department, ESA was responsible for the identification and scientific assessment of all licensing, collaboration, and acquisition opportunities for Merck and had responsibilities in the negotiation of agreements. Greg managed a group of 85 scientists, medical doctors, negotiators, paralegals, and administrators, distributed worldwide and divided by various therapeutic and platform areas, who identified and assessed opportunities outside of Merck’s walls.

Subscribe Today

Get the latest insights from RBC Capital Markets delivered to your inbox.